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ABSTRACT
Clerocidin (CL), a diterpenoid natural product, alky-
lates DNA through its epoxide moiety and exhibits
both anticancer and antibacterial activities. We have
examined CL action in the presence of topoisomerase
IV from Streptococcus pneumoniae. CL promoted
irreversible enzyme-mediated DNA cleavage leading
to single- and double-stranded DNA breaks at specific
sites. Reaction required the diterpenoid function: no
cleavage was seen using a naphthalene-substituted
analogue.Moreover,drug-inducedDNAbreakagewas
not observed using a mutant topoisomerase IV (ParC
Y118F) unable to form a cleavage complex with DNA.
Sequenceanalysisof102single-strandedDNAbreaks
and 79 double-stranded breaks revealed an over-
whelming preference for G at the 1 position, i.e.
immediately 50 of the enzyme DNA scission site.
This specificity contrasts with that of topoisomerase
IV cleavage with antibacterial quinolones. Indeed, CL
stimulated DNA breakage by a quinolone-resistant
topoisomerase IV (ParC S79F). Overall, the results
indicate that topoisomerase IV facilitates selective
irreversible CL attack at guanine and that its cleavage
complex differs markedly from that of mammalian
topoisomerase II which promotes both irreversible
and reversible CL attack at guanine and cytosine,
respectively. The unique ability to form exclusively
irreversible DNA breaks suggests topoisomerase IV
may be a key intracellular target of CL in bacteria.
INTRODUCTION
Clerocidin (CL) (Figure 1) is a natural drug (1), which has
been shown to inhibit bacterial DNA gyrase and eukaryotic
DNA topoisomerase II (2,3). CL differs from other known
topoisomerase poisons since it can induce the formation of
a cleavage complex, which is partially stable to heat and salt
treatment (3). In particular, the sequence specificity of
CL-stimulated eukaryotic topoisomerase II-mediated DNA
damage showed that when the base immediately preceding
the site of enzyme attack, i.e. position 1, was a guanine
(G), the cleavage was irreversible, whereas in the case of a
cytosine (C), the cleavage was reversible (4,5).
CL can also induce irreversible damage per se on single-
stranded DNA regions (6). The C12–C15 moiety of the drug is
responsible for the cleavage activity; in particular, sponta-
neous DNA fragmentation derives from depurination at the
G level caused by the electrophilic attack of the epoxide ring of
CL on the N7 group of exposed Gs (6). The hemi-acetalic form
of the a-ketoaldehyde function at C14–C15 enhances epoxide
reactivity by applying additional strain to the oxirane ring (7).
On the other hand, the diterpenoid portion of CL is dispensable
for drug activity per se; in fact the NA1 analogue of CL
(Figure 1), which preserves the C12–C15 ring but has the
diterpenoid function substituted with naphthalene retains
intrinsic DNA cleavage activity (7).
The modes of CL activity towards the DNA in the absence
or presence of a mammalian topoisomerase II are distinctive.
Direct CL-stimulated DNA damage requires longer reaction
times (6–24 h versus 30 min for the enzyme) and, unlike the
topoisomerase II-mediated reaction (4,5), the results are irre-
versible at both G and C nucleotides (7,8). Therefore, topoi-
somerases substantially modulate CL activity towards DNA.
Studies of CL potentiation have focussed almost entirely on
mammalian topoisomerase II. However, CL also exhibits
antibacterial activity against Escherichia coli and Gram-
positive pathogens, such as Staphylococcus aureus (2,3).
Moreover, it retains potency against Gram-positive (but not
E.coli) isolates resistant to quinolones, another class of
antibacterial topoisomerase poison. These properties raise
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the issue of whether the bacterial type II enzymes topoiso-
merase IV and gyrase are targeted by CL and potentiate its
action. Although topoisomerase IV and gyrase share important
common features with eukaryotic topoisomerase II, such as
homology and acting through a double-strand DNA break,
nevertheless their detailed mechanisms of action and quater-
nary organization appear to be individually different. Thus,
eukaryotic topoisomerase II controls the global topology of
DNA (9–11) whereas DNA gyrase unwinds replicating DNA
by introducing negative supercoils, while topoisomerase IV
decatenates interlocked daughter chromosomes (12–14). The
mechanism of topoisomerase II-catalyzed reactions and
the interaction of these enzymes with the DNA are hence
inevitably different: for instance, eukaryotic topoisomerase
II binding to DNA protects 25–28 bp (15), similar to topoi-
somerase IV (34 bp) (16), and gyrase wraps about 150 bp of
nucleic acid (17). Given that CL reactivity with the DNA rests
on the accessibility of nucleic acid reactive functions (6),
distinct DNA processing by bacterial topoisomerases could
result in a different CL poisoning mode to that observed for
mammalian topoisomerase II.
Early data have reported on CL activity against (E.coli)
gyrase, the quinolone target in Gram-negative species (2,3),
but surprisingly no information is available for CL action
towards topoisomerase IV, the primary target of many quino-
lones in Gram-positive bacteria, such as S.aureus and
Streptococcus pneumoniae (18,19). To gain insight on CL
mechanism potentially relevant to its antibacterial properties,
we have investigated its interaction with S.pneumoniae topoi-
somerase IV, one of the best characterized bacterial type II
enzymes. We report that CL was able to poison S.pneumoniae
topoisomerase IV with unique sequence specificity and irre-
versibility different from those seen for eukaryotic topoiso-
merase II. In contrast to what is observed for drug activity
per se, both the electrophilic C12–C15 ring and the diter-
penoid moiety were required for CL enzyme-mediated bio-
logical activity. By using a mutant topoisomerase IV (ParC
Y118F) we found that the enzyme must be covalently bound to
the DNA to promote irreversible CL damage. Finally, CL was
active against a quinolone-resistant topoisomerase IV but with
differences in DNA cleavage specifity to the wild-type protein,
which provide new insights on drug-induced poisoning of
topoisomerase IV.
MATERIALS AND METHODS
Chemicals and reagents
CL was a kind gift of Leo Pharmaceutical Products (Ballerup,
Denmark). NA1 was generously provided by Prof. S. Kobaya-
shi (University of Tokyo, Japan). CL and NA1 were dissolved
in absolute ethanol and the concentration determined by mea-
suring absorbance in ethanol at 230 and 282 nm on a UV/VIS
Spectrometer Lambda 12 (Perkin Elmer, MA). Molar extinc-
tion coefficients were experimentally determined to be
11 818 M1 cm1 for CL and 9493 M1 cm1 for NA1.
Working drug solutions were obtained by diluting fresh stocks
in the appropriate buffer. In each assay, the final ethanol
concentration was 2%. Ciprofloxacin (CPF) was provided
by GlaxoSmithKline (Verona, Italy). Stock solutions were
made in mQ-grade water and diluted to the working concen-
tration in the desired buffer. Buffer components were purchased
from Sigma–Aldrich (St. Louis, MO) and electrophoretic
reagents, dNTPs and Taq polymerase were from Amersham
Biosciences Europe (Freiburg, Germany). [g-32P]ATP was
from Perkin Elmer (MA); T4 polynucleotide kinase and
EcoRI were purchased from Invitrogen (Paisley, UK).
Topoisomerases IV from S.pneumoniae
E.coli BL21(lDE3)(pLysS) was from our laboratory collec-
tion. Conditions for growth of bacterial strains were as
described previously (18). S.pneumoniae ParC and ParE sub-
units were expressed as His-tagged proteins in E.coli
BL21(lDE3)(pLysS) from plasmids pXP13 and pXP14,
which contain the respective parC and parE genes cloned
from strain 7785, as described previously (20) except that
cells were induced with 0.4 mM isopropyl-b-D-thiogalactopy-
ranoside (IPTG) and protein expression was carried on for 12
h at 16C. This modification allowed the recovery of soluble
protein in greater yield. The proteins were purified to >95%
homogeneity by nickel chelate column chromatography and
exhibited specific activities of >2 · 105 U/mg when they were
assayed with an excess of the complementing subunit (20).
ParC S79F protein, whose purity and activity were comparable
to those of their wild-type counterpart, was obtained similarly
(21). ParC Y118F was prepared by expression from parC
plasmid pXP13 or pEL1 (22) whose parC codon 118 had
been altered using the QuikChange Site-Directed Mutagenesis
Kit (Stratagene) following the manufacturer’s instructions.
The mutagenic primers used for PCR were MUTFOR
(GATCCTCCTGCGGCTATGCGTTTTACTGAGGCACGT-
TTGTCT) and MUTREV (AGACAAACGTGCCTCA-
GTAAAACGCATAGCCGCAGGAGGATC). MUTFOR
corresponds to nucleotide positions 330–372 in parC, and
carries a T instead of A at position 352. Therefore the
codon (underlined) specifies phenylalanine instead of tyrosine
at position 118. After 1 h incubation at 37C with DpnI, which
digests the parental DNA template, the solution containing the
circular mutated plasmid was used to transform E.coli
XL1-Blue. Colonies of interest were analysed and sequenced;
the correct plasmid was transformed into BL21(lDE3)pLysS.
The expression and purification of ParC Y118F was performed
as described previously (20). Recombinant proteins were
examined by SDS–PAGE, and shown to be more than 95%
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Figure 1. Chemical structures of CL and its analogue NA1, both shown in the
cyclic hemiacetal form.
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homogeneous. Protein concentration was determined by
Bradford assay and SDS–PAGE.
DNAs
Plasmid pBR322 and SV40 DNA were purchased from MBI
Fermentas (MD) and Invitrogen (Paisley, UK), respectively.
Kinetoplast DNA from Crithidia fasciculata was obtained
from Topogen, Inc., (Ohio). Primers were purchased from
Eurogentec (Liege, Belgium) and were named according to
the nucleotide position of their 50 end in the SV40 sequence.
Primer sequences are as follows: pr658: GAGGCTCCT-
GGTGGTG; pr883: CTTTGTGATCCCAGTCAC; pr1640:
GAGGCTCCTGGTGGTG; pr1402: TGAAGCTGTCTACTC-
CAG; pr2026: TGCTCAAACTGTAACCCC; pr2261:
GCCCAACACCCTGCTC; pr3368: CTCTGGACTCCC-
CTCCA; pr3586: CTCTGGACTCCCCTCCA; pr4457:
GAGAGTCAGCAGTAGCC; pr4697: CCTTACTTCTGTG-
GTGTG; pr2533: GATCCAGACATGATAAG; pr2757: AGC-
CATACCACATTTGTA. These primers were used in PCR to
amplify 239 bp fragments using SV40 DNA as template.
50 end-labeling of primers and PCR
For primer labeling, 10 pmol of primer solution were incu-
bated with 2 ml (10 mCi/ml) of [g-32P]ATP and 10 U of T4
polynucleotide kinase in 50 mM Tris–HCl (pH 7.5), 7 mM
MgCl2 and 10 mM DTT, at 37
C for 30 min. After incubation,
DNA was ethanol precipitated and the labelled primers were
used to amplify 239 bp fragments of SV40 by PCR. Each
PCR was prepared by mixing 200 mM dNTPs, the pellet of
the ethanol precipitated labelled primer, 10 pmol of the cold
primer, 50 ng of template SV40 DNA and 5 U of Taq
polymerase in PCR buffer [10 mM Tris–HCl (pH 9.0),
50 mM KCl and 1.5 mM MgCl2] to a final volume of
100 ml. PCR cycles were 94C for 30 s, 55C for 30 s and
72C for 30 s (30 cycles). DNA fragments were then purified
with a QIAquick PCR purification kit (Qiagen, CA). The
resulting labelled fragments encompass 27% of the total
sequence of SV40.
Topoisomerase catalytic and cleavage assays
For decatenation assays, standard reaction mixtures (20 ml)
contained 40 mM Tris–HCl (pH 7.5), 6 mM MgCl2, 10 mM
DTT, 200 mM potassium glutamate, 1 mM ATP, 50 mg/ml of
BSA, 180 ng of kDNA and reconstituted topoisomerase IV
(0.03 mg ParC and 0.10 mg ParE), in the presence of different
drug concentrations. Reaction mixtures were incubated at
37C for 1 h, and then loading buffer (50% glycerol, 0.2%
xylene cyanol) was added. The treated samples were then
loaded on a 1% agarose gel in TBE [89 mM Tris, 89 mM
boric acid and 2 mM EDTA (pH 8.0)]. Gels were run at 70 V
for 120 min and stained with ethidium bromide; DNA bands
were visualized with a GelDoc 1000 ultraviolet (UV) transil-
luminator (Bio-Rad, Milan, Italy) and their intensity quantified
by Bio-Rad ImageQuant software.
For DNA cleavage assays, reconstituted topoisomerase
IV (0.45 mg ParC and 1.7 mg ParE) was incubated with
400 ng of supercoiled pBR322 in 25 ml reaction mixtures
[40 mM Tris–HCl (pH 7.5), 6 mM MgCl2, 10 mM DTT,
200 mM potassium glutamate, 50 mg/ml BSA], in the presence
of different drug concentrations. After a 30 min incubation at
37C, 1 ml of 10% SDS and 2 ml of a 20 mg/ml stock of
proteinase K were added, and incubation continued for 30
min at 45C. Loading buffer (3 ml) was added to the samples,
which were then analysed by electrophoresis in a 1% agarose
gel in TBE containing ethidium bromide at 50 mg/ml. The
linearized standard was obtained by incubating pBR322
with EcoRI in 10 mM Tris–HCl, 3.8 mM MgCl2 and 20
mM NaCl (pH 8.0), at 37C for 1 h. Cleavage assays were
also performed using labelled PCR products as DNA
substrates. In this case, after the incubation with SDS and
proteinase K, samples were ethanol precipitated, then resus-
pended in formamide gel loading buffer [95% formamide,
200 mM EDTA (pH 8.0), 0.1% (w/v) xylene cyanol and
0.1% (w/v) bromophenol blue] and heated at 90C for
5 min. Cleavage products were resolved in 8% polyacry-
lamide, 7 M urea gels alongside a G+A ladder obtained
according to the Maxam and Gilbert protocol (23). Gels
were then transferred to Whatman 3 MM filter paper, dried
under vacuum at 80C and bands were visualized by
phosphorimaging analysis (Molecular Dynamics, Amersham
Biosciences Europe). Quantification was performed by Image-
Quant software (Molecular Dynamics).
Statistical tests
The c2 one-sample test was used to determine the deviation
from the random distribution of bases at each position of the
aligned sequences (24). The expected occurrence of each
nucleotide was calculated considering the oligonucleotide fre-
quencies on the whole SV40 DNA (A ¼ T ¼ 0.296; C ¼ G ¼
0.204). Also, nucleotide preference was calculated by com-
puting the standard deviation (SD) of the expected frequency
p: SD ¼ (p[1  p]/n)1/2, where p ¼ 0.296 for A or T and
p ¼ 0.204 for G or C, and n is the number of sites analysed
in the dataset. A total of 99.9% confidence interval was then
calculated [p ± 3.3 SD]. Base frequencies outside confidence
intervals were considered significant. The probability (P) of
deviation from expectation was calculated as described
previously (24,25). Briefly, the expected number of sites
having a given base at any particular position is pn. Let
m be the observed number of sites, which have the
given base at that position. If m > pn, the probability P of
the chance occurrence of m or more instances was
calculated as
P ¼
Xn
i¼m
pið1  pÞðniÞðn!Þ/½i!ðn  iÞ!	
If m < pn, the chance occurrence of m or fewer instances was
calculated as follows:
P ¼
Xm
i¼0
pið1  pÞðniÞðn!Þ/½i!ðn  iÞ!	
Negative values of the logarithm of P, log(P), are reported
for each base at each position around the cleavage site.
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RESULTS
CL stimulates S.pneumoniae topoisomerase
IV-mediated DNA cleavage
CL activity against S.pneumoniae topoisomerase IV was
examined for both the catalytic and cleavage activities of
the enzyme. In the enzymatic assay, the ability of the enzyme
to decatenate kDNA was exploited. In the absence of the drug,
topoisomerase IV converted all the input kDNA to free mini-
circles, (lane 2, Figure 2A). CL partially inhibited enzyme
activity at 100 mM, but was essentially inactive at lower
doses (EC50 >200 mM; lanes 8–12, Figure 2A). CPF, a
known topoisomerase IV inhibitor, was used as a positive
control (lanes 3–7, Figure 2A). This fluoroquinolone impaired
enzyme activity above 100 mM, as shown by the presence of
unlinked input kDNA and of intermediate forms of catenated
DNA (EC50 80 mM; lanes 6 and 7, Figure 2A). These data for
CPF are consistent with previous observations (20,26).
For cleavage experiments, the supercoiled form of plasmid
pBR322 was incubated with topoisomerase IV in the absence
or presence of increasing drug concentrations. DNA breakage
was induced by addition of SDS, and following proteinase K
digestion, the DNA was examined by agarose gel electrophor-
esis (Figure 2B). In the absence of the drug, the enzyme
converted 15% of the plasmid into the nicked form
(lane 2, Figure 2B). When CL was added, the drug-induced
detectable single-strand DNA breaks (producing nicked form
plasmid) in a dose-dependent fashion, starting from a concen-
tration of 25 mM, (lanes 6–10, Figure 2B). At higher concen-
trations, CL also induced double-strand DNA cleavage
generating dose-dependent increases in the linear DNA
(lanes 8–10, Figure 2B). For any given DNA sample, the
percentage of nicked, linear and supercoiled DNA bands
were determined by dividing the relevant band intensity by
the total DNA intensity loaded into that particular track. At
200 mM concentration, CL generated 55 and 16% of the
nicked and linear form, respectively, while reduced the
supercoiled DNA to 34%. CPF produced both single- and
double-strand cleavage at DNA concentrations as low as
5 mM (lanes 3–5, Figure 2B). At 20 mM quinolone concen-
tration, the nicked, linear and supercoiled form were 50,
18 and 32%, respectively (20,26).
To accurately estimate CL efficiency in stabilizing topoi-
somerase IV-mediated cleavage, we studied the intensity
patterns of DNA breaks stimulated by CL or CPF on a 50
end 32P-labelled SV40 DNA segment amplified by PCR.
After SDS and proteinase K treatment, reaction mixtures
were loaded on denaturing urea–polyacrylamide gels to sepa-
rate DNA fragments. Drug concentrations were gradually
increased from 60 nM to 250 mM (Figure 2C). Under these
conditions, cleavage detected was the sum of single-strand and
double-strand breaks: the minimal concentrations for CL- and
CPF-mediated DNA fragmentation were 16 and 1 mM, respec-
tively (lanes 11 and 20, Figure 2C). The EC50 was 69 and 13
mM for CL and CPF, respectively.
CL topoisomerase IV-mediated cleavage
is selective for G bases
From the cleavage assay reported in Figure 2C, it is clear that
CL induced a specific DNA fragmentation pattern that was
different from that of CPF. In order to analyse DNA sequence
requirements for CL action, six 239 bp-long SV40 segments
were 32P-labelled on the forward or reverse strand indepen-
dently, and amplified by PCR to obtain 27% coverage of the
total SV40 sequence. All DNAs were next incubated with
topoisomerase IV in the presence of CL and the cleavage
patterns were analysed as described above. We were able to
collect a large set of CL-mediated cleavage sites, 260 in total.
Sequences of cleavage sites were aligned at the point of the
phosphodiester bond break in the 50!30 orientation, and bases
immediately 50 and 30 to the cut were numbered 1 and +1,
respectively. Positions 1 and +5 are equivalent to topoiso-
merase IV-mediated DNA double-strand breaks since they are
adjacent to each site of cleavage. From a total of 260 strand
cuts that were sequenced, 102 (39%) lacked a 4 bp staggered
break on the complementary strand.
The deviation of base distribution from the global SV40
DNA base frequencies was first evaluated at each position
(± 20 from the cleavage site) by c2 analyses (Figure 3A). A
core region of non-random base composition was found
between positions 5 and +10. In particular, the most strik-
ingly biased positions were 1 and +5. Positions 4, 5 and
+8, +9 were also slightly preferred, while the centre of the core
region (positions from +1 to +4) and positions 2, 3 and +6,
+7 showed no preferential base selection. Next, probabilities
of the observed base frequency deviations from expectation
(G ¼ C ¼ 20.4%; A ¼ T ¼ 29.6%) at each position were
assessed for the non-complementary sites (102 in total) and
complementary sites (79 on each strand) independently (total
260 sites). When considering the complementary set, 47 and
54 out of 79 sites on the forward and reverse strand, respec-
tively, at positions 1 were guanines, which corresponds to
logP values of 19.3 and 13.4 (Figure 3B). Likewise, 54 and
49 cytosines out of 79 bases (forward and reverse strands,
respectively) were found at position +5, which corresponds
to logP values of 19.3 and 15.0 (Figure 3B). On the other
hand, T and A at positions 1 and +5 were notably dis-
favoured (logP 9.28 and 3.97, respectively). In the non-
complementary set, G remained largely preferred at position
1 (logP 35.9), while T and A were again disfavoured
(logP 10.25 and 5.75, respectively); conversely no
base preference or disfavour were detected at position +5
(Figure 3C). It should be noted that logP values >3 corre-
espond to <0.1% possibility that the preference arose by
chance. Therefore, the observed preferences are very strong
indeed.
Comparing sequence specificity of topoisomerase
IV-mediated cleavage stimulated by CL or by our control
quinolone drug, CPF, we observed that about 25% of
CL-stimulated sites were shared with CPF sites and, vice
versa, 16% of CPF-stimulated sites were shared with CL.
Of all sites exhibiting a G at position 1 stimulated by
CPF, 42% were also cleaved by CL.
CL-induced topoisomerase IV-mediated DNA
damage is irreversible
All known anti-topoisomerase II drugs show cleavage
reversibility upon salt addition or incubation at high tempera-
ture (27,28). In contrast, CL was reported to possess the unique
capability of poisoning human and murine topoisomerase II in
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Figure 2. CL poisons topoisomerase IV. (A) Inhibition of the decatenation activity of the enzyme. Kinetoplast DNA (kDNA) was incubated with topoisomerase IV
and increasing amounts (12.5, 25, 50, 100, 200 mM) of CPF, (lanes 3–7) or CL (lanes 8–12). Reaction mixtures were loaded and run on a 1% agarose gel. DNA bands
were visualized with ethidium bromide staining. Lane 2 is a control for topoisomerase enzymatic activity in the absence of the drugs and lane 1 is a control for the input
kDNA. M denotes released minicircle DNA. Pk indicates partially catenated DNA intermediates. (B and C) Stimulation of enzyme-mediated DNA breaks.
(B) Supercoiled plasmid pBR322 was incubated with increasing amounts of CPF (5, 10, 20 mM, lanes 3–5) or CL (12.5, 25, 50, 100, 200 mM, lanes 6–10) and loaded
on a 1% agarose gel. DNA bands were visualized with ethidium bromide staining. Lane 2 is a control for the cleavage activity of topoisomerase IV without drugs. Lane
1 shows the input supercoiled plasmid DNA and lane 11 is a control for linear plasmid DNA. Band identities are shown on the left. N, L and SC indicate nicked, linear
and supercoiled plasmid DNA, respectively. For any given DNA sample, the percentage of nicked, linear and supercoiled DNA bands were determined by dividing
the relevant band intensity by the total DNA intensity loaded into that particular track. Quantification data are shown below the gel figure. (C) A 239 bp SV40 DNA
fragment, labelled with 32P at one 50 end, was incubated with topoisomerase IV and increasing amounts (60 nM–256 mM) of CL (lanes 3–15) or CPF (lanes 16–28).
Reaction mixtures were loaded and run on a denaturing urea-8% polyacrylamide gel. DNA fragments were visualized by phosphorimaging. Lane 1 and 2 are controls
for non-treated DNA and DNA incubated with the enzyme without drugs. Lane 29 and 30 are respective G+A and G sequencing products obtained according to the
Maxam and Gilbert protocol (23). Drug concentrations present in cleavage reactions are shown at the bottom of the gel.
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a partially salt- and temperature-independent manner (4,5). To
determine if this characteristic was maintained against bacte-
rial topoisomerase IV, CL was incubated with a 50 end
32P-labelled SV40 DNA fragment in the presence of topoiso-
merase IV for 20 min at 37C; then, either 0.6 M NaCl was
added and incubation continued for 10 min, or the incubation
temperature was increased to 65C for 10 min. As shown in
Figure 4, none of the CL-stimulated cleavage sites were
reversed by either treatment (compare lanes 7 and 8 with 6,
Figure 4), whereas the totality of CPF-induced sites displayed
reversion (compare lanes 4 and 5 with 3, Figure 4). In other
experiments (data not shown) we found that EDTA was
similarly unable to reverse CL-stimulated DNA cleavage by
topoisomerase IV.
CL is inactive when topoisomerase IV is unable
to cleave DNA
In order to understand whether enzyme-mediated DNA cleav-
age was a prerequisite for irreversible CL-mediated DNA
damage, CL activity was measured against a mutant topoiso-
merase IV reconstituted with Y118F ParC. This enzyme is able
to bind the DNA, but lacks the active site tyrosine residue
necessary for the covalent nucleophilic attack and phospho-
diester bond breakage involved in DNA breakage-reunion.
Consequently, the enzyme is inactive in topoisomerase and
cleavage assays. The ability of topoisomerase IV Y118F to
bind double-stranded DNA was assayed by band shift analysis:
enzymes containing the wild-type and mutant ParC subunits
were able to bind the nucleic acid with similar efficiency
(E. Leo and L. M. Fisher, unpublished data). Experiments
with CL showed that the drug did not stimulate DNA cleavage
by the mutant enzyme (data not shown).
Quinolone-resistant topoisomerase IV reconstituted
with S79F ParC alters CL activity
To investigate enzymatic residues potentially involved in CL
poisoning, we assayed CL against a mutant topoisomerase IV
carrying an S79F substitution in ParC that confers resistance to
Figure 3. Sequence analysis of CL-stimulated DNA cleavage by topoisomerase IV. (A) c2 values of the base distribution at positions ranging from10 to +10 of the
sites of CL stimulation of DNA cleavage. The number 1 indicates the base 50 of the cleaved phosphodiester bond identified in sequencing gels. (B and C)
Probabilities of the observed base frequency deviations from expectation at each position on the forward strand of complementary sites (B) and non-complementary
sites (C) (data for the reverse strand are reported in the text). In the ordinate, P is the probability of observing that deviation or more, either as an excess (above base
line) or deficit (below base line) relative to the expected frequency of each base. The expected frequencies were calculated using the overall base frequency of SV40
DNA (G ¼ C ¼ 20.4%; A ¼ T ¼ 29.6%).
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quinolones (29). As shown in Figure 5, DNA fragmentation in
the presence of CL indicated that the drug was active on the
mutant enzyme (lanes 10 and 11, Figure 5). Interestingly,
though the overall cleavage pattern resembled that of the wild-
type protein, it was apparent that five out of nine cleavage sites
were absent or markedly reduced in intensity when using the
mutant topoisomerase IV (compare lanes 8 and 9 with 10 and
11, see sites labelled with an asterisk, Figure 5). As expected,
the control drug CPF induced DNA fragmentation with the
wild-type topoisomerase IV but not with the mutant enzyme
(compare lanes 6 and 7 with 4 and 5, Figure 5). The same assay
was repeated with two additives non-complementary SV40-
based PCR amplified fragments: a total of 11 CL-induced sites
were found decreased in intensity with the mutant topoiso-
merase IV compared with wild-type enzyme. Of these, eight
had 1 G; hence the base frequency at the cleavage site
remained the same as that observed with the wild-type enzyme
(see Figure 3). However, the region between positions +2 and
+5 showed a moderately enhanced frequency of G/C
nucleotides; in particular the preferred base at position
+2 was G for five sites, whereas C was preferred at positions
+3 (4 Cs and 3 Gs), +4 (4 Cs and 1 G) and +5 (5 Cs and 3 Gs).
It appears that CL cleavage by the mutant enzyme is sensitive
to the base composition of the DNA that lies within the 4 bp
staggered break induced by topoisomerase IV.
The diterpenoid portion of CL is necessary for
topoisomerase IV poisoning
Recent work has shown that the diterpenoid portion of CL
(Figure 1) is dispensable for DNA damage in the absence of a
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Figure 5. CL-stimulated DNA cleavage in the presence of wild-type topoi-
somerase IV or mutant quinolone-resistant enzyme reconstituted with ParC
S79F. A 50 end 32P-labelled 239 bp-long SV40 DNA segment was incubated
with wild-type (lanes 2, 4–5, 8–9) or S79F mutant topoisomerase IV (lanes 3,
6–7, 10–11) and 25–50 mM of CPF (lanes 4–7) or CL (lanes 8–11) at 37C for
30 min. Reaction mixtures were stopped and run on a 8% denaturing poly-
acrylamide gel. DNA fragments were visualized by phosphorimaging. Lane 1 is
a control for the untreated input DNA. Lanes 2–3 are controls for wild-type and
S79F mutant topoisomerase IV-processed DNA, respectively. Arrows on the
right of the gel indicate cleavage bands and asterisks specify cleavage sites that
are differently induced by CL-stimulated wild-type and S79F mutant enzymes.
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D
TopoIV
Figure 4. Irreversibility of CL-stimulated topoisomerase IV-mediated DNA
cleavage sites. A 50 end 32P-labelled 239 bp-long SV40 DNA segment was
incubated with topoisomerase IV and 25 mM of CPF (lanes 3–5) or 100 mM of
CL (lanes 6–8) at 37C for 20 min. Samples in lanes 4 and 7, and 5 and 8 were
further treated with 0.6 M NaCl for 20 min (indicated as RS) or 65C for 20 min
(indicated as RT), respectively. Stopped reaction mixtures were loaded and run
on a 8% denaturing polyacrylamide gel. DNA fragments were visualized
by phosphorimaging. Lane 1 and 2 are controls for untreated DNA (D) and
topoisomerase IV-processed DNA, respectively.
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topoisomerase (7). To test whether this holds true for topoi-
somerase IV-mediated cleavage, DNA fragmentation was
measured in the presence of NA1, an analogue of CL in
which the diterpenic function is substituted with a naphthalene
moiety (Figure 1). Freshly-made CL and NA1 solutions were
incubated either with 32P-labelled PCR amplified DNA and
topoisomerase IV for 30 min, or with supercoiled pBR322
plasmid for 24 h (Figure 6). Surprisingly, NA1 did not induce
any cleavage (lanes 8–12, Figure 6) in the presence of the
enzyme, unlike CL which was able to induce strand breaks
resulting in marked plasmid nicking (lanes 3–7, Figure 6)
(52, 17 and 31% of the nicked, linear and supercoiled form,
respectively, at 200 mM CL concentration), as described
above. Concurrently, in the absence of the enzyme, NA1
was confirmed to be essentially as effective as CL in promot-
ing plasmid DNA cleavage after 24 h incubation at 37C,
while at shorter reaction times (30 min) both drugs generated
little cleavage (data not shown) (5,7). To rule out the possi-
bility of enzymatic inhibition by NA1, the drug was tested in a
topoisomerase IV decatenation assay, which showed that it
was unable to inhibit enzymatic activity at concentrations
up to 400 mM (data not shown). Thus, the diterpenoid moiety
of CL is important for reaction with topoisomerase IV.
DISCUSSION
We have established that CL, an antimicrobial DNA alkylating
agent, mediates single- and double-stranded DNA cleavage by
S.pneumoniae topoisomerase IV. By characterizing the
enzyme-, drug- and sequence-determinants, we could show
that the reaction has a number of unique features, notably
its irreversibility, the overwhelming preference for attack at
guanine bases and differences in sequence specificity and
selectivity with CPF, an antibacterial topoisomerase IV poi-
son. These and other data indicate that CL reacts in a unique
manner with the cleavage complex of topoisomerase IV and
suggest that the enzyme may contribute to the antibacterial
action of the drug.
Initial studies revealed that whereas CL is a poor inhibitor
of DNA decatenation by topoisomerase IV requiring high
drug concentrations (EC50 >100 mM) (Figure 2A), stimulation
of topoisomerase IV-mediated DNA cleavage was effective
at lower CL levels and increased in a dose-dependent fashion.
When CL and topoisomerase IV were incubated with super-
coiled plasmid DNA and nucleic acid breaks were visualized
by ethidium bromide, drug effects were manifest at 25 mM
(Figure 2B). When the drug and the enzyme were instead used
against a 32P-labelled 239 bp linear DNA fragment, DNA
damage was apparent at lower CL concentrations (16 mM)
due to the higher sensitivity of the detection method
(Figure 2C). In both experiments, CL was about five times
less potent than the control antibacterial fluoroquinolone CPF
(calc. EC50 69 mM and 13 mM for CL and CPF, respectively).
In this regard, CL activity is similar to that described with
murine topoisomerase II: in fact eukaryotic enzyme-mediated
CL damage at the DNA level was assessed at 25 mM and was
25–2.5 times less potent than the control anti-topoisomerase II
drugs (5).
CL-promoted DNA cleavage by topoisomerase IV occurred
at specific sites (Figure 2C) and could not be reversed by prior
incubation with high salt or high temperature, in contrast to
CPF-promoted cleavage that occurred at a different spectrum
of sites and was completely reversible (Figure 4). Within the
260 CL-stimulated strand scission sites that we identified and
sequenced, we distinguished two subsets: complementary sites
arising from double-strand breaks and non-complementary
sites resulting from single-stranded DNA breakage. Statistical
analysis of base frequency deviations from expectation
showed in both cases an overwhelming preference for G at
the cleavage site (position 1) (Figure 3). The complementary
set, where sites were analysed independently for the forward
and reverse sequences, attested also to a comparable prefer-
ence for C at position +5, indicating that the vast majority of
complementary sites bear a 1 G at the cleavage site on
both complementary strands. On the other hand, the non-
complementary set of sites lacked this symmetry and exhibited
1 G only on the cut strand. All CL-stimulated cleavage sites
were found fully irreversible upon heat or salt treatment.
These results obtained with the bacterial topoisomerase IV
are significantly different from those reported for murine
topoisomerase II. In fact, in the case of topoisomerase II,
the base immediately preceding the site of enzyme attack
was either G or C; in addition, the cleavage was irreversible
at G sites, but reversible at Cs which comprise one-third of the
sites (4,5). A mechanism for the biased behaviour toward G
and C in the presence of the eukaryotic enzyme has been
proposed. According to the model, the N7 of G is exposed
to efficient alkylation by the drug, which blocks enzymatic
re-ligation and thereby stabilizes DNA damage (6). In con-
trast, the NH2 and N3 reactive sites of C, being involved in
base pairing, remain effectively protected from CL alkylation.
Hence, the C preference is promoted by non-covalent
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Figure 6. The CL analogue NA1 does not promote topoisomerase IV-mediated
DNA breakage. Supercoiled plasmid pBR322 was incubated with increasing
amounts (12.5, 25, 50, 100, 200 mM) of CL (lanes 3–7) or NA1 (lanes 8–12) and
after SDS-proteinase K treatment, DNA products were separated on a 1%
agarose gel and visualized by ethidium bromide staining. Lanes 1 and 2 are
controls for the input supercoiled plasmid DNA and for the cleavage activity of
topoisomerase IV without drugs, respectively. Band identities are shown on the
left. N, L and SC stand for nicked, linear and supercoiled plasmid DNA,
respectively. For any given DNA sample, the percentage of nicked, linear
and supercoiled DNA bands were determined by dividing the relevant band
intensity by the total DNA intensity loaded into that particular track. Quanti-
fication data are shown below the gel figure.
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interaction with the drug and, in this model, CL behaves like a
classical topoisomerase poison (8).
We note that CL stimulation of topoisomerase IV-mediated
cleavage is in general asymmetric. If G is present at the 1
position of both strand-breakage sites, CL induces a double-
strand break. If G is present at the 1 position of one of the
two strand-breakage sites, CL induces a single-strand break.
If G is absent at the 1 position, CL does not affect the
strand-breakage and reunion activity of topoisomerase IV.
This feature is consistent with our present observation of
weak inhibition of topoisomerase IV enzymatic activity in
a decatenation assay (Figure 2A). Thus, these results revealed
the molecular basis of topoisomerase poisoning by CL and
suggested that, as is the case with human topoisomerase II
(30), topoisomerase IV could ligate the two scissile bonds of a
cleavage site in a non-concerted manner.
It is known that, in the absence of enzyme and at longer
reaction times, the electrophilic attack of the CL epoxide on
N7 of Gs on locally unpaired regions (i.e. bulges) can induce
strand breaks per se (6). Therefore, we assessed whether
topoisomerase-mediated DNA cleavage was a condition for
CL-mediated nucleic acid damage in the presence of the
enzyme. For this purpose, we used a mutant topoisomerase
IV reconstituted with ParC in which the catalytic Tyr 118 had
been replaced with Phe (Y118F). The mutant topoisomerase
IV was able to bind DNA non-covalently and possibly distort
it, but was inactive in DNA breakage-reunion. In fact, CL
failed to damage the DNA in the presence of the mutant
enzyme, indicating that covalent topoisomerase–DNA inter-
actions are required for enzyme-related CL activity. This
result supports the idea that CL stimulates cleavage at G
nucleotides that are already ‘processed’ by the enzyme i.e.
positioned at the new 30 end of the transient enzyme-induced
strand break. Heightened reactivity of the 1G in the cleavage
complex coupled with proper alignment of CL via enzyme
binding to the deterpenic portion (Figure 6) presumably
account for the much shorter DNA reaction times observed
for CL in the presence of enzyme.
The sequence specificity of S.pneumoniae topoisomerase
IV-mediated cleavage induced by CL is dramatically different
from that of quinolones. In the case of the diterpenoid drug, G
is always preferred at the cleavage site (1 position), while a
wider consensus DNA sequence (2A, +1G, +4C, +6T) is
driven by quinolones, with no specific base requirement at
position 1 (22). Were CL to force the enzyme to cut the
DNA at the G level, then one would expect cleavage at every G
in DNA. On the contrary, only a subset of Gs is cleaved. We
propose that CL cleaves only those G nucleotides that are first
processed by topoisomerase IV. The fact that no more than
42% of 1G sites stimulated by CPF are shared with CL
indicates that the cleavage sites preferred by the two families
of drugs are only partially overlapping.
It is intriguing that the ParC S79F mutation that confers
enzyme resistance to quinolones, also affected CL poisoning
activity (Figure 5). In fact, even though incubation of CL with
the S79F mutant enzyme still induced strand scission and G
remained the base largely preferred at the cleavage site,
nonetheless, some sites exhibited a dramatic reduction in
cleavage intensity compared to the response with wild-type
enzyme. Analysis of base frequency at positions 20 to +20
for sites which were less efficiently cleaved by the mutant
topoisomerase IV revealed that, again, G was preferred at
position 1. Thus, base preference at the cleavage site itself
did not discriminate the differential effects found for the wild-
type and mutant enzymes. However, in sites whose cleavage
was reduced using the quinolone-resistant enzyme, positions
from +2 to +5 were particularly rich in G/C nucleotides. Base
pairs in this region must be separated during the topoisomerase
enzymatic cycle in order to permit strand passage, and many
topoisomerase poisons, such as quinolones, are accommo-
dated between the two split DNA strands (22). The mutated
ParC residue at position 79 is close in the primary sequence to
the active site tyrosine (Y118) and confers high-level resis-
tance to quinolones. We speculate that the S79 ParC residue is
somehow involved in promoting or stabilizing DNA strand
separation between the two staggered cuts. Although the mut-
ant topoisomerase IV remains active, it possibly separates
complementary DNA strands less efficiently. This would be
particularly evident when the nucleic acid sequence is rich in
strongly hydrogen-bonded G/C base pairs. As a consequence,
for sites rich in GC base pairs at positions +2 to +5, CL would
fail to reach its G target (and induce irreversible cleavage) due
to insufficient distortion of the adjacent double helical DNA
region. It should be noted that topoisomerase IV reconstituted
with ParC S79F is comparably active to wild-type enzyme in
catalysis (29). Therefore, based on our results, DNA unpairing
within the staggered break would not be the limiting step in the
topoisomerase IV catalytic cycle.
Finally, the ability of CL to poison the S79F mutant topoi-
somerase IV may help explain data found on drug activity in
earlier work. CL was reported to be inactive versus several
quinolone-resistant Gram-negative bacterial strains, whereas it
remained active against quinolone-resistant Gram-positive
S.aureus (2). Since topoisomerase IV is the major quinolone
target in Gram-positive bacteria, we propose that susceptibility
of the quinolone-resistant S.aureus to CL arises from the con-
tinued sensitivity of the mutated topoisomerase IV to the diter-
penoid drug. On the other hand, gyrase is mainly poisoned in
Gram-negative bacteria and indeed mutations in the gyrA gene
produced cross-resistance to quinolones and CL in resistant
strains (2). Further progress on these issues will require studies
of CL targeting in bacteria.
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